- Oral presentation
- Open Access
Subtle structural abnormalities in genotype positive phenotype ‘negative’ patients with pre-clinical hypertrophic cardiomyopathy (HCM): a blinded, controlled cardiovascular magnetic resonance (CMR) study
© Deva et al; licensee BioMed Central Ltd. 2012
- Published: 1 February 2012
- Cardiovascular Magnetic Resonance
- Mutation Carrier
- Hypertrophic Cardiomyopathy
- Subtle Sign
- Subtle Abnormality
To evaluate the utility of cardiovascular magnetic resonance (CMR) in detection of individuals with pathogenic/ presumed pathogenic (PA/ PP) sarcomeric mutations and gene negative patients with high clinical probability of HCM but with a negative phenotype by standard diagnostic criteria.
Mutation carriers without hypertrophy - gene positive, phenotype negative (G+P-) - are not uncommon in clinical practice. There is debate about the presence of subtle abnormalities or variants of the left ventricle in G+P- individuals. Previous research into this area only evaluated limited mutations in the myosin binding protein C and α-tropomyosin genes. We hypothesized: 1) that G+P- patients with pathogenic or presumed pathogenic (PA/PP mutations) have subtle abnormalities of LV morphology recognisable by CMR in pre-clinical HCM but absent in a control population; and 2) that these signs are also present in gene negative patients with a normal wall thickness (G-P-) but high clinical probability of HCM (based on assessment of clinical or family history, electrocardiographic or echocardiographic criteria).
The study population had 3 groups - Group 1 (G+P-, tested positive for PA/ PP mutations, n=18); Group 2 (G-P-, Under evaluation for HCM, tested negative for [PA/ PP] mutations, n=20); and Group 3 (controls, n=36). Two experienced CMR readers (blinded to results of genetic testing and clinical context) scored each case for probability of the case representing HCM based on pre-defined signs at CMR including the presence/absence of: a) deep basal inferoseptal crypts (DBISC); b) sudden wall thickness change by >50% in adjacent segments (SWTC); c) inappropriate wall thinning (IWT); d) apical-basal false tendon (ABFT); e) lack of apical tapering (LAT); f) snub nose apical contour (SNAC) . Cases were reviewed individually and in consensus. An experienced HCM cardiologist (blinded to CMR findings) reviewed clinical data, electrocardiograms and echocardiograms and scored each case for likelihood of HCM.
Of the 18 G+P- patients, 78% had DBISC, 67% had an ABFT, 50% had IWT and 39% had SWTC. DBISC were seen in cases with PA/PP MYBPC3, TPM1, TNNT2 and MYH7 mutations. All G+P- cases had at least one subtle sign. All G-P- cases classified clinically as high probability of HCM, were classified as high probability of HCM on imaging grounds and had 2 or more subtle signs of HCM: DBISC, SWTC, IWT, ABFT, SNAC and LAT. Controls had no DBISC, SWTC, IWT or LAT.
Subtle structural abnormalities visible on CMR help identify PA/PP sarcomeric mutation carriers, as well as G- P- with high clinical probability of HCM, in a genetically heterogenous population.
Incidence of Subtle Signs in G+P- Group and Controls
G+P- Group (n=18)
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.